AI
ICPT

Axiom Investors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Axiom Investors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,416
Closed -$3.22M – 157
2015
Q1 		$3.22M Buy
+11,416
New +$2.47M 0.09% 92

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Axiom Investors's ICPT Position: Q2 2015 in Review

Axiom Investors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2015, closing a stake of 11,416 shares — an estimated $3.22M sold.

Axiom Investors first reported a position in ICPT in Q1 2015 and held it in 1 quarter. The position peaked at $3.22M in Q1 2015. 191 funds tracked by Wall St. Rank hold ICPT as of Q2 2015.

  • Axiom Investors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Axiom Investors sold 11,416 Intercept Pharmaceuticals, Inc. shares in Q2 2015, an estimated $3.22M.
  • Axiom Investors first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Axiom Investors's Intercept Pharmaceuticals, Inc. position peaked at $3.22M in Q1 2015.
  • 191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2015.

Based on Axiom Investors's 13F filing for Q2 2015, filed 13 Aug 2015.